# Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

> **NCT00519532** · PHASE3 · TERMINATED · sponsor: **UCB Pharma** · enrollment: 84 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Rotigotine

## Key facts

- **NCT ID:** NCT00519532
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-07
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Due to clinical trial supplies shortage
- **Last updated:** 2014-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519532, "Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00519532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*